Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant strains

M. E. Pachón-Ibáñez, F. Docobo-Pérez, M. E. Jiménez-Mejias, J. Ibáñez-Martínez, A. García-Curiel, C. Pichardo, J. Pachón

► To cite this version:

M. E. Pachón-Ibáñez, F. Docobo-Pérez, M. E. Jiménez-Mejias, J. Ibáñez-Martínez, A. García-Curiel, et al.. Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant strains. *European Journal of Clinical Microbiology and Infectious Diseases*, 2011, 30 (7), pp.895-901. 10.1007/s10096-011-1173-6 . hal-00671830

HAL Id: hal-00671830

<https://hal.science/hal-00671830>

Submitted on 19 Feb 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Efficacy of rifampin, in monotherapy and combination, in an experimental murine pneumonia model caused by panresistant *Acinetobacter baumannii* strains

María Eugenia Pachón-Ibáñez PhD*[#], Fernando Docobo-Pérez PhD[#], Manuel Enrique Jiménez-Mejías MD, PhD, José Ibáñez-Martínez MD, PhD, Andrés García-Curiel MD, PhD, Cristina Pichardo MD, PhD, Jerónimo Pachón MD, PhD.

From the Infectious Diseases Services (MEPI, FDP, MEJM, CP, JP) and Service of Microbiology (AGC), Institute of Biomedicine of Sevilla (IBIS), University Hospital Virgen del Rocío/CSIC/University of Sevilla, Sevilla, Spain, and Department of Pathology (JIM), University Hospital Virgen Macarena, Sevilla, Spain.

* Corresponding author. Mailing address:

Dr. María Eugenia Pachón Ibáñez

Mailing address: Department of Immunology and Microbial Science. SP30-2110, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.

Phone: (858) 784 7079; E-mail: meniapi@hotmail.com

[#] MEPI and FDP contributed equally to the manuscript.

ABSTRACT

The objective of this work was to evaluate the efficacy of rifampin, and its combinations with imipenem or sulbactam, in an experimental pneumonia model caused by two panresistant *A. baumannii* strains (HUV99, HUV113). MICs and MBCs ($\mu\text{g/ml}$) of the strains were: rifampin 128/ >128 for both strains, imipenem 128/ >256 and 256/ >256 for HUV99 and HUV113, respectively, and sulbactam >256 / >256 for both strains. In time-kill studies, at MIC concentrations, rifampin was bactericidal for both strains and sulbactam against HUV99 strain. Rifampin plus imipenem or sulbactam, at MIC or mice C_{max} , were synergistic. *In vivo*, against HUV99 and HUV113, rifampin (73% and 40%) and its combinations improved the survival respect to the control group (20% and 0%, $p<0.05$), respectively. Rifampin (87% and 46%) and its combinations improved the sterilization of blood cultures, respect to the control groups (0%, $p<0.05$). In regard with the bacterial clearance from lungs, rifampin (2.57 ± 2.47 and 5.35 ± 3.03 $\log_{10}$ cfu/g) and its combinations with imipenem or sulbactam diminished the bacterial lung concentration respect to the control group (10.89 ± 3.00 and 11.86 ± 0.49 , $p<0.05$) with both strains. In conclusion, rifampin alone or associated to imipenem or sulbactam were effective for the treatment of murine pneumonia caused by selected panresistant *A. baumannii* strains.

Keywords: panresistant, *Acinetobacter baumannii*, experimental pneumonia model, rifampin, sulbactam, imipenem.

INTRODUCTION

Acinetobacter baumannii is an important nosocomial pathogen [1, 2], particularly in intensive care units settings. The treatment of these infections is challenged by the ability of this microorganism to acquire resistance to almost all antibiotics, including carbapenems [3, 4]. In these situations, alternative options are scarce, and only colistin and rifampin are active against these multidrug-resistant strains. Thus, colistin has been restored for the treatment of severe multidrug-resistant *A. baumannii* infections [5-7], although the mortality in infections as ventilator-associated pneumonia remains around 40%. However, infections caused by colistin-resistant strains have been reported [8-11] which have prompted to explore other alternative treatments for infections caused by these strains.

Montero *et al.* [12], using an experimental murine pneumonia model caused by carbapenem-resistant *A. baumannii* strains, found that the addition of colistin did not improve the efficacy of rifampin alone; on the contrary imipenem plus rifampin was more efficacious than rifampin's monotherapy. We also showed that rifampin was better than colistin in reducing bacterial lung concentration in an experimental murine pneumonia model caused by a carbapenem-resistant *A. baumannii*, and that the addition of colistin to rifampin did not improve its efficacy; however, imipenem or sulbactam plus rifampin decrease 1 log₁₀ cfu/g of lung compared with rifampin alone [13].

The aim of the present study was to evaluate the efficacy of rifampicin, associated to imipenem or sulbactam, against clinical isolates of panresistant *A. baumannii*, including resistance to colistin, using an experimental murine pneumonia model.

MATERIAL AND METHODS

Bacterial strains. We used two bacteriaemic panresistant *A. baumannii* strains (HUVR99 and HUVR113) belonging to the same clone responsible for an outbreak in our hospital [8]. Isolates were identified as *A. baumannii* by means of Gram staining, observation of their colonial morphology and motility, use of cytochrome oxidase reaction analysis, determination of whether there was growth at 44° C, as well as by the use of a semiautomated microbiology system (MicroScanWalk-Away; Dade-Behring). Additionally, the strains were confirmed as *A. baumannii* by the use of amplified ribosomal DNA restriction analysis [14].

Antibacterial agents and drugs. In the *in vitro* assays, antibacterial agents were used as laboratory standard powders: imipenem (Merck, Sharp & Dohme, Madrid, Spain), sulbactam (PharmaSierra, Madrid, Spain), and rifampin and colistin sulfate (Sigma-Aldrich, Madrid, Spain). For the *in vivo* experiments, we used imipenem and sulbactam as commercial vials from the same manufacturers as above, and rifampin from Aventis (Madrid, Spain). Sodium thiopental (5% wt/vol) was provided by B. Braun Medical S.A. (Barcelona, Spain).

Susceptibility testing and time-kill curve experiments. MICs and MBCs were determined according standard methods [15,16]. *Escherichia coli* ATCC 25922 was used as a control strain. The breakpoints for resistance were those defined by the Clinical and Laboratory Standards Institute [15], and the French Society for Microbiology for rifampin [16].

Time-kill kinetic assays were conducted on Mueller-Hinton broth (MHB) at drug concentrations of MIC and $C_{\max}$ (peak drug serum concentration in C57BL/6 female healthy mice, after a single dose of 30 mg/kg intramuscularly (i.m.) for imipenem, 60

mg/kg i.m. for sulbactam, and 25 mg/kg intraperitoneally (i.p.) for rifampin. A control without antibiotics was evaluated in parallel. The initial inoculum was approximately 10^5 cfu/ml. Cultures were incubated at 37°C and bacterial counts were determined by plating 100 µl of ten-fold dilutions of control or test tubes, onto sheep blood agar plates (SBA), at 0, 2, 4, 8, and 24 h. Plates were incubated for 24 h at 37°C. Bactericidal activity was defined as ≥ 3 log₁₀ decrease of the initial inoculum in cfu/ml [17].

In vitro synergies of rifampin plus imipenem or sulbactam against the two strains were tested with time-kill assays. Concentrations of MIC or $C_{\max}$ of each antibacterial agent were used. Synergy was defined as ≥ 2 log₁₀ decreases in bacterial concentration, in comparison with the most active drug alone [18].

The *in vitro* experiments were performed in duplicate. Moreover, MIC and MBC were repeated periodically to check that the susceptibilities of both strains did not change during the *in vivo* experiments.

Animals. Immunocompetent C57BL/6 female mice, weighing 16 to 20 g, obtained from the University of Sevilla's facility were used. The *in vivo* studies were approved by the Ethics Committee of the Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Drug pharmacokinetics. Serum drug levels were determined in groups of 21 healthy mice after administration of a single dose of each antibacterial agent. The dosages administered were: 30 mg/kg/i.m. for imipenem, 60 mg/kg/i.m. for sulbactam, and 25 mg/kg/i.p. for rifampin. After 10, 15, 30, 60, 90, 120, and 150 min, blood samples were drawn from the periorbital plexus of three anesthetized mice per time-point. Drug concentrations were measured by a bioassay method, using *Micrococcus luteus* ATCC 9341, *Bacillus subtilis* 6633, and *A. baumannii* ATCC 19606 as control strains [19].

Maximum plasma concentration ($C_{\max}$, $\mu\text{g/ml}$), terminal half-life ($t_{1/2}$, hours), and AUC ($\mu\text{g}\cdot\text{h/ml}$) were calculated by a computer-assisted method (<http://www.boomer.org/pkin/soft.html>). The time during which the plasma concentration remained above the MIC ($\Delta\text{T/MIC}$, hours) was estimated by extrapolation from the regression line of plasma elimination.

Experimental pneumonia model in mice. A murine experimental pneumonia model was carried out using *A. baumannii* HUVR99 and HUVR113 strains [20]. Anesthetized animals were infected transtracheally with a final inoculum of approximately 10^8 cfu/ml in 50 μl of the bacterial suspension mixed 1:1 with porcine mucin (Sigma-Aldrich) diluted to 10% in saline.

Antibacterial treatment. Mice were randomly ascribed into four treatment groups, for 72 h: control (non-treated), rifampin (100 mg/kg/day/i.p., q.i.d.), rifampin plus imipenem (120 mg/Kg/day/i.m., q.i.d.), and rifampin plus sulbactam (240 mg/Kg/day/i.m., q.i.d.).

Because the strains used in these experiments were resistant to **antibacterial agents**, the dosages were those showing efficacy in an experimental pneumonia model caused by multidrug-resistant *A. baumannii* [13]. These dosages obtained, for imipenem and sulbactam, plasma concentrations in the ranges of those reached in humans after standard dosing for severe infections [21]. For rifampin, the dosage obtains an AUC similar to that found in humans [22].

Therapy was initiated 4 h after the bacterial challenge, when histological features of pneumonia appeared [20]. Animals were observed for 72 h for mortality, and surviving mice were sacrificed 4 h after the last **antibacterial agent** dose by the administration of sodium thiopental; all the mice were analyzed immediately after death. Thoracotomy

was carried out and 100 µl of blood, collected by cardiac puncture, was cultured in TSB for 24 h at 37°C and then 100 µl was plated on SBA plates and incubated for another 24 h at 37°C; results were expressed as positive or negative. Heart and lungs were extracted in block and lungs were separated onto a sterile Petri plate, weighed, and processed for quantitative culture after being homogenized (Stomacher 80 Tekmar Co., Cincinnati, Ohio, USA) in 2 ml of sterile saline solution. After 10-fold dilution, aliquots of 100 µl were plated onto SBA plates for 24 h at 37°C. If cultures were negative, lungs were considered sterile, when no growth was observed after plating the whole residue of the homogenized tissue onto SBA plates. Results were expressed as means $\pm$ standard deviations of the log₁₀ cfu/g of lung.

Lung samples were processed for pathological studies in five mice from each control group. Lungs were fixed with 10% formaldehyde and embedded in paraffin and cut into 4 µm thick sections. The slices included all the pulmonary lobes to be studied by optical microscopy. They were processed according to standard methods for hematoxylin-eosin, periodic acid-Schiff, Gram, Masson's trichromic, and silver reticulin stains.

To confirm that the **antibacterial** treatments were not toxic to the animals, groups of 5 randomly non-infected mice were each given the antibiotics for 72 h.

Statistical analysis. Therapeutic efficacy in each experiment was assessed comparing the lung bacterial counts and the percentages of bacteremia and mortality among the groups. Numbers of surviving animals and negative blood cultures were evaluated with the Fisher's exact test. The cfu/g of lung tissue was analyzed using the homogeneity of variance (ANOVA) and posthoc tests (Tukey-Kramer and Dunnet test). The SPSS 14.0 statistical package (SPSS Inc., Chicago, IL) was used. A *P* value of 0.05 was considered significant.

RESULTS

***In vitro* studies.** MIC and MBC of imipenem, sulbactam, rifampin, and colistin for *A. baumannii* HUVR99 and HUVR113 are shown in Table 1.

For the time-kill experiments (Fig. 1 and 2) MIC >256 µg/ml were fixed at 256 µg/ml. Against HUVR99 sulbactam was bactericidal at MIC at 8 h and at a concentration of C_{max} at 24 h, and rifampin at MIC at 4 and 8 h; against HUVR113 only rifampin at MIC was bactericidal at 4 h. For both strains, synergy was found with rifampin plus imipenem at both concentrations, MIC and C_{max} . Rifampin plus sulbactam was synergistic at MIC for HUVR99 and at MIC and C_{max} for HUVR113.

Pharmacokinetic studies. The pharmacokinetic and pharmacodynamic parameters of each antibacterial agent are shown in Table 2. The $\Delta T/MIC$ for all the antibacterial agents was 0 hours for both strains.

Pathological studies. The mice groups inoculated with strains HUVR99 and HUVR113 showed alterations compatible with acute pneumonia. They presented acute inflammation, characterized by diffuse and/or focal affectation of all lobes, with a mild to severe inflammatory infiltration of polymorphonuclear cells (PMN), sometimes forming segmentary abscesses, and with mild to moderate infiltration of alveolar macrophages. Gram-negative bacterial colonies and alveolar hemorrhagic areas were also observed.

Therapeutic efficacy in experimental pneumonia. *In vivo* efficacy of the antibacterial agents against both *A. baumannii* strains is shown in Table 3. Survival rates in the

control groups were 20% and 0% for strains HUVR99 and HUVR113, respectively. For both, all the treatments improved survival rates compared with their controls ($P < 0.05$), with no difference among the different treatments. In the sterilization of blood cultures, for the strain HUVR99 all the treatments were efficacious ($P < 0.05$) compared with the control group, with no difference among the **antibacterial agents**. For the strain HUVR113 only rifampin and its combination with sulbactam increased the number of sterile blood cultures (46% and 93.3% *versus* 0%, respectively); moreover, rifampin plus sulbactam was better than the other treatments (93.3% *versus* 46% and 21%, $P < 0.05$). Against both *A. baumannii* strains, HUVR99 and HUVR113, all treatment groups decreased the lung bacterial counts when compared with the controls ($P < 0.05$). While for strain HUVR99 there was no differences in lung clearance among the treatment groups, against the HUVR113 rifampin plus sulbactam produced higher lung clearance than that obtained with rifampin alone or combined with imipenem (2.33 ± 1.43 *versus* 5.35 ± 3.03 and 6.80 ± 2.19 , respectively [$P < 0.05$]). No toxicity was observed in the non-infected mice with the different therapies given during 72 h.

DISCUSSION

The present study shows that rifampin and its combinations with imipenem or sulbactam are efficacious in the experimental pneumonia model caused by two *A. baumannii* panresistant strains, in terms of diminished mortality and clearance of bacteria from blood and lung tissue. In general, rifampin alone showed the same efficacy that their combinations, but rifampin plus sulbactam were better than the monotherapy with rifampin in the clearance of bacteria from blood and lung against one

of the strains. These results are in accordance with the synergistic effect found in the time-kill studies with this combination.

This therapeutic efficacy of rifampin agrees with the results found in several experimental murine pneumonia models, using multiresistant *A. baumannii* strains. Wolff *et al.* in a pneumonia model in neutropenic mice caused by using two *A. baumannii* strains with different susceptibilities to rifampin [23], 8 and 4 µg/ml respectively, observed improved survival and decrease in bacterial lung concentration with rifampin. Montero *et al.* in an immunocompetent murine pneumonia model [12], reported similar results with three *A. baumannii* strains with MIC of rifampin of 8 µg/ml. We also observed [13], in two experimental animal models of pneumonia in immunocompetent mice and meningitis in rabbits, using an imipenem-resistant *A. baumannii* strain with a MIC of rifampin of 4 µg/ml, the therapeutic efficacy of this antibacterial agent alone and in combination, also in terms of improved survival and decrease of bacterial lung concentration.

Saballs *et al.* treated 10 patients with *A. baumannii* infections with rifampin plus imipenem [24], curing eight cases in spite of the development of resistance to rifampin in seven cases caused by strains with MIC of imipenem of >256, 128, and 64 µg/ml in 5, 1, and 1, respectively.

The mechanisms by which rifampin was active in the experimental pneumonia caused by highly-rifampin-resistant *A. baumannii* remains to be elucidated. The first may be the synergistic *in vitro* effect of the two combinations, rifampin plus imipenem or sulbactam, avoiding the regrowth of *A. baumannii* at 24 hours at C_{max} , except in the case of imipenem in the HUV99 strain, suggesting the usefulness of these combinations for the treatment of infections by panresistant *A. baumannii*. Other possibilities deserved posterior studies.

Some **antibacterial agents**, such as macrolides (clarithromycin or erythromycin), azalides (azithromycin) and ketolides (telithromycin), present higher levels at the infection site, than that found in plasma [25], due to the accumulation in PMN or epithelial lining fluid. Fluoroquinolones, such as ciprofloxacin, also present much higher concentrations in the lung tissue than in plasma [26]. Respect to rifampin, previous studies have shown accumulation inside PMN cells [27] or in alveolar macrophages, reaching 16.26 times the plasmatic concentration (251.8 and 15.1 µg/ml, respectively) [28]. These accumulations could explain the effectiveness of rifampin in the treatment of pulmonary infections. In this way, the effectiveness of rifampin in the experimental pneumonia model by panresistant *A. baumannii* strains may be due to an accumulation of the drug in the alveolar macrophages, sufficient to eradicate the infection caused by this pathogen, or its transport to the infection site by PMN cells.

The conditions in which a drug interacts with a pathogen *in vivo* are different to those in which the studies are carried out *in vitro*. Thus, the pH of the lung, infection site in the experimental model of *A. baumannii* of the present study, has an acid pH opposed to the neutral pH of the medium in which the MIC is determined. This lower pH alters the effectiveness of the **antibacterial agents** [29]. Therefore, one hypothesis is that the acidity of pH of the lung could increase the susceptibility of the *A. baumannii* to rifampin.

Rifampin has two major active metabolites, 25-O-deacetyl rifampin produced by deacetylation at hepatic level, and 3-formyl rifamycin SV produced by hydrolysis at acid pH. Both are detectable in serum and urine [30, 31]. It may be that the *A. baumannii* strains, used in this study, display a greater susceptibility to these metabolites than to rifampin. This could explain why the rifampin is more active against *A. baumannii* in

269 *vivo* that *in vitro*, since in this last situation the metabolites derives from rifampin
270 would not be generated.

271 In summary, the results of the present study suggest that rifampin and its combinations
272 with imipenem or sulbactam may be efficacious in the treatment of pulmonary
273 infections caused by panresistant strains of *A. baumannii*. However, because the high
274 MIC of rifampin against the *A. baumannii* strains used in this study, the mechanisms of
275 this *in vivo* experimental efficacy of rifampin must be elucidated, before the evaluation
276 of this therapy in humans.

ACKNOWLEDGMENTS

This work was supported by research grants from the Consejería de Salud de la Junta de Andalucía (13/02) and the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III - co-financed by European Development Regional Fund "A way to achieve Europe" ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD06/0008/0000).

The results of this manuscript were presented in the 15th ECCMID, Copenhagen, Denmark, 2005.

REFERENCES

1. Rodríguez-Baño J, Cisneros JM, Fernández-Cuenca F et al (2004) Clinical features and epidemiology of *Acinetobacter baumannii* colonization and infection in Spanish hospitals. Grupo de Estudio de Infección Hospitalaria (GEIH). Infect Control Hosp Epidemiol 25:819-824.
2. Rodríguez-Baño J, García L, Ramírez E et al (2009) Long-term control of hospital-wide, endemic multidrug-resistant *Acinetobacter baumannii* through a comprehensive "bundle" approach. Am J Infect Control 37:715-722.
3. Michalopoulos A, Falagas ME (2010) Treatment of *Acinetobacter* infections. Expert Opin Pharmacother 11:779-788.
4. McGowan JE Jr (2006) Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Infect Control 34 (Suppl 1):S29-37; discussion S64-73.
5. Falagas ME, Kasiakou SK, Tsiodras S et al (2006) The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 4:138-146.
6. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ et al (2003) Treatment of multidrug-resistant *Acinetobacter baumannii* ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36:1111-1118.
7. De Pascale G, Pompucci A, Maviglia R, Spanu T, Bello G, Mangiola A et al (2010) Successful treatment of multidrug-resistant *Acinetobacter baumannii* ventriculitis with intrathecal and intravenous colistin. Minerva Anestesiol. May 6. [Epub ahead of print].

- 313 8. Valencia R, Arroyo LA, Conde M et al (2009) Nosocomial outbreak of infection
314 with pan-drug-resistant *Acinetobacter baumannii* in a tertiary care university
315 hospital. Infect Control Hosp Epidemiol 30:257-263.
- 316 9. Cisneros-Herreros JM, Garnacho-Montero J, Pachón-Ibáñez ME (2005)
317 Nosocomial pneumonia due to *Acinetobacter baumannii*. Enferm Infecc
318 Microbiol Clin 23 (Suppl 3):46-51.
- 319 10. Li J, L Nation R, Owen RJ, Wong S, Spelman D, Franklin C (2007)
320 Antibigrams of multidrug-resistant clinical *Acinetobacter baumannii*:
321 Promising therapeutic options for treatment of infection with colistin-resistant
322 strains. Clin Infect Dis 45:594-598.
- 323 11. Ko KS, Suh JY, Kwon KT, et al (2007) High rates of resistance to colistin and
324 polymyxin B in subgroups of *Acinetobacter baumannii* isolates from Korea. J
325 Antimicrob Chemother 60:1163-1167.
- 326 12. Montero A, Ariza J, Corbella X, et al (2004) Antibiotic combinations for serious
327 infections caused by carbapenem-resistant *Acinetobacter baumannii* in a mouse
328 pneumonia model. J Antimicrob Chemother 54:1085-1091.
- 329 13. Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R, et al (2010) Efficacy of
330 rifampin and its combinations with imipenem, sulbactam, and colistin in
331 experimental models of infection caused by imipenem-resistant *Acinetobacter*
332 *baumannii*. Antimicrob Agents Chemother 54:1165-1172.
- 333 14. Vaneechoutte M, Dijkshoorn L, Tjernberg I, et al (1995). Identification of
334 *Acinetobacter* genomic species by amplified ribosomal DNA restriction
335 analysis. J Clin Microbiol 33:11-15.

- 336 **15.** Clinical and Laboratory Standards Institute (2010) Performance standards for
337 antimicrobial susceptibility testing; Twentieth informational supplement.
338 Document M100-S20. Clinical and Laboratory Standards Institute, Wayne, Pa.
- 339 **16.** Société Française de Microbiologie (2010) Comité de l'antibiogramme de la
340 Société Française de Microbiologie, SFM, Paris. (www.sfm.asso.fr, accessed
341 August 11, 2010).
- 342 **17.** National Committee for Clinical Laboratory Standards (1999) Methods for
343 Determining Bactericidal Activity of Antimicrobial Agents: Approved Standard
344 M26-A. NCCLS, Wayne, PA, USA.
- 345 **18.** Pillai SK, Moellering RC Jr, Eliopoulos GM (2005) Antimicrobial
346 combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine. 5th ed.
347 Philadelphia: Lippincott Williams & Wilkins, pp 365-440.
- 348 **19.** Klein RD, Edberg SC (2005) Applications, significance of, and methods for the
349 measurement of antimicrobial concentrations in human body fluids In: Lorian V,
350 ed. Antibiotics in Laboratory Medicine. 5th ed. Philadelphia: Lippincott
351 Williams & Wilkins, pp 290-364.
- 352 **20.** Rodríguez-Hernández MJ, Pachón J, Pichardo C, et al (2000) Imipenem,
353 doxycycline and amikacin in monotherapy and in combination in *Acinetobacter*
354 *baumannii* experimental pneumonia. J Antimicrob Chemother 45:493-501.
- 355 **21.** Amsden GW (2010) Tables of antimicrobial agent pharmacology. In: Mandell
356 GL, Bennett JE, and Dolin R, eds. Principles and practice of infectious diseases.
357 7th ed. Philadelphia: Churchill Livingstone Elsevier, pp 705-761.
- 358 **22.** Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE
359 (2007) Pharmacokinetics and tolerability of a higher rifampin dose versus the

standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 51: 2546-2551.

23. Wolff M, Joly-Guillou ML, Farinotti R, Carbon C (1999) *In vivo* efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against *Acinetobacter baumannii* in a mouse pneumonia model. Antimicrob Agents Chemother 43:1406-1411.

24. Saballs M, Pujol M, Tubau F, et al (2006) Rifampicin/imipenem combination in the treatment of carbapenem-resistant *Acinetobacter baumannii* infections. J Antimicrob Chemother 58:697-700.

25. Drusano GL (2005) Infection site concentrations: Their importance and the macrolide and macrolide-like class of antibiotics. Pharmacotherapy 25:150S-158S.

26. Bamberger DM, Foxworth JW, Bridwell DL, Shain CS, Gerding DN (2005) Extravascular antimicrobial distribution and the respective blood and urine concentrations in humans. In: Lorian V, ed. Antibiotics in Laboratory Medicine. 5th ed. Philadelphia: Lippincott Williams & Wilkins, pp 719-814.

27. Prokesch RC, Hand LW (1982) Antibiotic entry into human Polymorphonuclear leukocytes. Antimicrob Agents Chemother 21:373-380.

28. Ziglam HM, Baldwin DR, Daniels I, Andrew JM, Finch RG (2002) Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 50:1011-1015.

29. Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F (2006) Pharmacodynamic evaluation of intracellular activities of antibiotics

against *Staphylococcus aureus* in a model of THP-1 macrophages. Antimicrob Agents Chemother 50:841-851.

30. Inderlied CB, Nash KA (2005) Antimycobacterial agents: *In vitro* susceptibility testing and mechanism of action and resistance. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Philadelphia: Lippincott Williams & Wilkins, pp 155-225.

31. Weber A, Opheim KE, Smith AL, Wong K (1983) High-pressure liquid chromatographic quantitation of rifampin and its two major metabolites in urine and serum. Rev Infect Dis 5:S433-S439.

Table 1. MIC and MBC of imipenem, sulbactam, rifampin, and colistin for HUVR99 and HUVR113 *A. baumannii* panresistant strains.

Antibacterial agents	MIC / MBC (µg/ml)	
	Strain HUVR99	Strain HUVR113
Imipenem	128 / >256	>256 / >256
Sulbactam	>256 / >256	>256 / >256
Rifampin	128 / >128	128 / >128
Colistin	32 / >32	32 / >32

MIC: minimal inhibitory concentration

MBC: minimal bactericidal concentration

Table 2. Pharmacokinetic and pharmacodynamic parameters of imipenem, sulbactam, and rifampin in mice.

Antimicrobial agents (dose)	$C_{\max}$ ($\mu\text{g/ml}$)	$t_{1/2}$ (h)	AUC_{0-t} ($\mu\text{g}\cdot\text{h/ml}$)	$C_{\max}/\text{MIC}$	$\text{AUC}_{0-24\text{ h}}/\text{MIC}$
Imipenem (30 mg/kg)	23.25	0.26	11.29	0.18 ^a 0.09 ^b	0.35 ^a 0.18 ^b
Sulbactam (60 mg/kg)	89.45	0.35	87.51	0.35 ^{a,b}	1.36 ^{a,b}
Rifampin (25 mg/kg)	15.75	2.86	24.76	0.12 ^{a,b}	0.77 ^{a,b}

^a Parameter calculated for the strain HUVR99.

^b Parameter calculated for the strain HUVR113.

$C_{\max}$: The maximum plasma concentration; $t_{1/2}$: terminal half-life; AUC_{0-t} : area under the concentration-time curve; $C_{\max}/\text{MIC}$, peak concentration above the MIC; $\text{AUC}_{0-24\text{ h}}/\text{MIC}$, area under the concentration-time curve above the MIC (256 $\mu\text{g/ml}$ for sulbactam in both strains and imipenem in the strain HUVR113).

Table 3. *In vivo* therapeutic efficacy of rifampin (RIF), imipenem (IPM), sulbactam (SB) and its combinations in the experimental pneumonia by *A. baumannii* HUVR99 and HUVR113.

Treatment	<i>A. baumannii</i> HUVR99				<i>A. baumannii</i> HUVR113			
	n	Survival (%)	Sterile blood cultures (%)	Log cfu/g of lung $\pm$ S.D.	n	Survival (%)	Sterile blood cultures (%)	Log cfu/g of lung $\pm$ S.D.
Control	14	2 (20)	0 (0)	10.89 $\pm$ 3.00	15	0 (0)	0 (0)	11.86 $\pm$ 0.49
RIF	15	11 (73) ^a	13 (87) ^a	2.57 $\pm$ 2.47 ^a	15	6 (40) ^a	7 (46) ^a	5.35 $\pm$ 3.03 ^a
RIF + IPM	15	12 (80) ^a	13 (87) ^a	2.62 $\pm$ 1.74 ^a	15	5 (33) ^a	3 (21)	6.80 $\pm$ 2.19 ^a
RIF + SB	14	8 (60) ^a	10 (71.4) ^a	2.53 $\pm$ 2.28 ^a	15	8 (53) ^a	14 (93.3) ^{a,b}	2.33 $\pm$ 1.43 ^{a,b}

^a*P* < 0.05 compared with the control group.

^b*P* < 0.05 compared to the other treatment groups.

Fig 1. Time-kill assays of rifampin, imipenem, sulbactam, and the combinations of rifampin plus imipenem or sulbactam against *A. baumannii* HUVR99 at MIC and serum mice C_{max} .

Figure 1, legend. Control, filled diamond; rifampin (MIC), filled triangle; rifampin (C_{max}), open square; imipenem (MIC), filled square; imipenem (C_{max}), filled circle; sulbactam (MIC) open inverted triangle; sulbactam (C_{max}), open diamond; rifampin plus imipenem (MIC), open circle; rifampin plus imipenem (C_{max}), inverted filled triangle; rifampin plus sulbactam (MIC), open triangle; rifampin plus sulbactam (C_{max}), black cross.

Fig 2. Time-kill assays of rifampin, imipenem, sulbactam, and the combinations of rifampin plus imipenem or sulbactam against *A. baumannii* HUVR113 at MIC and serum mice C_{max} .

Figure 2, legend. Control, filled diamond; rifampin (MIC), filled triangle; rifampin (C_{max}), open square; imipenem (MIC), filled square; imipenem (C_{max}), filled circle; sulbactam (MIC) open inverted triangle; sulbactam (C_{max}), open diamond; rifampin plus imipenem (MIC), open circle; rifampin plus imipenem (C_{max}), inverted filled triangle; rifampin plus sulbactam (MIC), open triangle; rifampin plus sulbactam (C_{max}), black cross.